	UNITED KINGDOM				icial certificate to the EU	
	I.1 Consignor/Exporter		I.2 Certificate ref	erence	I.2a	
	Name					
	Address	I.3 Central Comp	etent Authority	/		
			DEPARTMENT FOF	OR ENVIRONMENT, AFFAIRS		
_			I.4 Local Compet	ent Authority	1 /	
		O country code	ANIMAL AND P	LANT HEALTH AGENCY		
	L5 Consignee/Importer		I.6 Operator responsible for the consignment			
	Name		Name			
ü	Address		Address			
Part I: Description of consignment	· 6					
on (O country code	Country		SO country code	
ptic	I.7 Country of origin ISC	O country code	I.9 Country of de	stination	ISO country code	
šcri						
Deg	I.8 Region of origin	de	I.10 Region of des	stination	Code	
; I :	I.11 Place of dispatch	egistration/Approval No	I.12 Place of desti	ination	Registration/Approval No	
)ar	THE TIME OF UISPANE	egistidiota i ippi a a ma	111211111111111111111111111111111111111	intion	Rogistiation, Tappe	
1	Name		Name			
	Address		Address			
	- 1001-222					
		(
	-	O country code	Country		SO country code	
	I.13 Place of loading		I.14 Date and tim			
	I.15 Means of transport		I.16 Entry Border	r Control Post		
	☐ Aircraft ☐ Vesse	el	I.17			
	□ Railway □ Road	vehicle				
	Identification					
-	I.18 Transport conditions	☐ Chilled ☐ Frozen				
-	I.19 Container number/Seal number	L Chined	L 1102	VII VIII		
	Container No	Seal No				
Ī	I.20 Certified as or for					
	☐ Germinal products					
	I.21		I.22	r internal market	L	
	Third country IS	SO country code	I.23		_	
	I.24 Total number of packages	I.25 Total quantity	7	I.26		

				II.a Certificat	e reference
	ED KINGDOM				
I.27 1	Description of co	onsignment			
	CN code	Species	Subspecies/Category	Identification number	Quantity
	Туре	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
2	CN code	Species	Subspecies/Category	Identification number	Quantity
	Civede	P	Subspecies/Category	identification number	Quality
	Туре	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
3	CN code	Species	Subspecies/Category	Identification number	Quantity
	Туре	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
4	CN code	Species	Subspecies/Category	Identification number	Quantity
		·		%	
	Туре	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test
5					
	CN code	Species	Subspecies/Category	Identification number	Quantity
	Туре	Approval or registration number of plant/establishment/centre	Identification mark	Date of collection/production	Test

II.a Certificate reference

UNITED KINGDOM

II. Health information

I, the undersigned official veterinarian, hereby certify that:

- II.1. The [oocytes] (1) [in vivo derived embryos] (1) [in vitro produced embryos] (1) [micromanipulated embryos] (1) described in Part I are intended for artificial reproduction and were obtained from donor animals which originate from a third country or territory, or zone thereof:
 - II.1.1. authorised for the entry into the Union of [oocytes]⁽¹⁾ [embryos] ⁽¹⁾ of [ovine] ⁽¹⁾ [caprine] ⁽¹⁾ animals and listed in Annex X to Commission Implementing Regulation (EU) 2021/404;
- where foot and mouth disease was not reported for at least 24 months immediately prior to the date of [collection] (1) [production] (1) of the [cocytes] (1) [embryos] (1) and until the date of their dispatch;]
- - where infection with rinderpest virus, infection with Rift Valley fever virus, infection with peste despetits ruminants virus, sheep pox and goat pox and contagious caprine pleuropneumonia were not reported for at least 12 months immediately prior to the date of [collection] (1) [production] (1) of the [oocytes] (1) [embryos] (1) and until the date of their dispatch;
 - where no vaccination against infection with rinderpest virus, infection with Rift Valley fever virus, infection with peste des petits ruminants virus, sheep pox and goat pox and contagious caprine pleuropneumonia has been carried out for at least 12 months immediately prior to the date of [collection] (1) [production] (1) of the [oocytes] (1) [embryos] (1) and until the date of their dispatch, and no vaccinated animals entered into the third country or territory, or zone thereof during that period, and:
 - [no vaccination against foot and mouth disease has been carried out for the same period and no vaccinated animals entered into the third country or territory, or zone thereof during that period;]
- (1) or [vaccination against foot and mouth disease has been carried out for the same period, or vaccinated animals entered into the third country or territory, or zone thereof during that period.]
- (1) [II.2. The [oocytes] (1) [in vivo derived embryos] (1) described in Part I have been collected, processed and stored, and dispatched by the embryo collection team (3) which:
 - II.2.1. is approved and listed by the competent authority of the third country or territory;
 - II.2.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686.]
- (1) [II.2. The [oocytes] (1) [in vitro produced embryos] (1) [interomanipulated embryos] (1) described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team (3) which:
 - II.2.1. is approved and listed by the competent authority of the third country or territory;
 - II.2.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.]
- II.3. The [oocytes] (1) [embryos] (1) described in Part I were obtained from donor animals which originate from establishments:
 - II.3.1. free from infection with *Brucella abortus*, *B. melitensis* and *B. suis* and they have never been kept previously in any establishment of a lower health status.
- (II.3.2. in which infection with *Mycobacterium tuberculosis* complex (*M. boyis, M. caprae* and *M. tuberculosis*) has not been reported during the last 42 days;
- which is subjected to surveillance to detect infection with *Mycobacterium tuberculosis* complex (*M. bovis, M. caprae* and *M. tuberculosis*) in caprine animals kept therein in accordance with procedures provided for in Part 1, points (1) and (2), of Annex II to Commission Delegated Regulation (EU) 2020/688 during at least 12 months and during that period:
 - (i) only caprine animals from establishments applying such surveillance have been introduced therein;
 - (i) either [(ii) infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis) has not been reported in the animals of the same species kept therein.]]
 - (1) or [(ii) infection with Mycobacterium tuberculosis complex (M. bovis, M. caprae and M. tuberculosis) has been reported in caprine animals kept therein and the measures were taken in accordance with Part 1, point 3, of Annex II to Delegated Regulation (EU) 2020/688.]]
 - II.3.3. in which:

(1) or

- (1) either [surra (Trypanosoma evansi) has not been reported in the establishments during the last 2 years.]
 - [surra (*Trypanosoma evansi*) has not been reported during the last 30 days and when the disease was reported in the establishments during the last 2 years, following the date of the last outbreak the establishments have remained under movement restrictions until the date on which the infected animals have been removed from the establishments, and the remaining animals in the establishments have been subjected to a test for surra with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, or samples taken at least 6 months after the date on which the infected animals have been removed from the establishments.]
- II.4. The [oocytes] (1) [embryos] (1) described in Part I were obtained from donor animals which:
 - II.4.1. were not vaccinated against infection with rinderpest virus, infection with Rift Valley fever virus, infection with peste des petits ruminants virus, sheep pox and goat pox and contagious caprine pleuropneumonia;
 - II.4.2. remained for at least 6 months immediately prior to the date of [collection] (1) [production] (1) of the [oocytes] (1) [embryos] (1) in a third country or territory, or zone thereof referred to in box I.7;
 - II.4.3. for at least 30 days immediately prior to the date of [collection] (1) [production] (1) of the [oocytes] (1) [embryos] (1) and during the [collection] (1) [production] (1) period:

Part II: Certification

Certificate model OV/CAP-OOCYTES-EMB-A-ENTRY

			Certificate model OV/CAP-OOCYTES-EMB-A-ENTRY
UNITED KINGDOM			II.a Certificate reference
	П.4.3.1.	mouth diseas petits rumina	establishments not situated in a restricted zone established due to the occurrence of foot and se, infection with rinderpest virus, infection with Rift Valley fever virus, infection with peste des ants virus, sheep pox and goat pox or contagious caprine pleuropneumonia, or of an emerging vant for ovine and caprine animals;
.5	II.4.3.2.	with Mycobo (Trypanoson (serotypes 1-	a single establishment where infection with <i>Brucella abortus</i> , <i>B. melitensis</i> and <i>B. suis</i> , infection acterium tuberculosis complex (<i>M. bovis</i> , <i>M. caprae</i> and <i>M. tuberculosis</i>), rabies, anthrax, surra na evansi), infection with epizootic haemorrhagic disease virus, infection with bluetongue virus -24) and, in case of ovine animals and those caprine animals which are kept together with ovine ne epididymitis (<i>Brucella ovis</i>) have not been reported;
0.	II.4.3.3.		contact with animals from establishments situated in a restricted zone due to the occurrence of erred to in point II.4.3.1 or from establishments which do not meet the conditions referred to in 2;
	II.4.3.4.	were not use	d for natural breeding;
11.4.4.			veterinarian or a team member and did not show symptoms or clinical signs of transmissible of [collection] (1) [production] (1) of the [oocytes] (1) [embryos] (1);
II.4.5.			s provided for in Article 21(1) of Delegated Regulation (EU) 2020/692;
II.4.6.	comply w II.4.6.1.	_	onditions as regards foot and mouth disease: com establishments:
		the estable [oocytes in which	in an area where foot and mouth disease has not been reported within a 10-km radius centred on blishments for at least 30 days immediately prior to the date of [collection] (1) [production] (1) of the s] (1) [embryos] (1); h foot and mouth disease has not been reported during at least 3 months immediately prior to the [collection] (1) [production] (1) of the [oocytes] (1) [embryos] (1);
(1) either	[II.4.6.2.	they were no	ot vaccinated against foot and mouth disease;]
(1)(6) or	[II.4.6.2.		accinated against foot and mouth disease during 12 months immediately prior to the date of the embryos and
		II.4.6.2.1.	have not been vaccinated against foot and mouth disease within at least 30 days immediately prior to the date of collection of the embryos;
		II.4.6.2.2.	the semen used for fertilisation was collected from a male donor that complies with the conditions set out in Part 5, Chapter I, point 1(b), of Annex II to Delegated Regulation (EU) 2020/686 or the semen complies with the conditions set out in Part 5, Chapter I, point 2, of Annex II to Delegated Regulation (EU) 2020/686;
		II.4.6.2.3.	prior to freezing, the embryos have been subjected to trypsin washing carried out in accordance with the recommendations of the IETS Manual (7);
		II.4.6.2.4.	the embryos were stored deep frozen for at least 30 days from the date of collection, and during this period the donor animal has not shown clinical signs of foot and mouth disease;]
II.4.7.	comply with		e following conditions as regards infection with bluetongue virus (serotypes 1-24):
⁽¹⁾ either	[II.4.7.1.	[embryos] ⁽¹⁾ in a 24) where no cas	ept for at least 60 days immediately prior to the date of and during collection of the [oocytes] (1) third country or territory, or zone thereof free from infection with bluetongue virus (serotypes 1-se of infection with bluetongue virus (serotypes 1-24) has been confirmed in the targeted animal g the last 24 months;]
(1)(14) or	[II.4.7.2.		ept in a seasonally disease-free zone, during the seasonally disease-free period, for at least 60 y prior to the date of and during collection of the [oocytes] (1) [embryos] (1);]
(1) and/or	[II.4.7.3.		ept in a vector-protected establishment for at least 60 days immediately prior to the date of and of the [oocytes] (1) [embryos] (1)]
(1) and/or	[II.4.7.4.		ubjected to a serological test able to detect specific antibodies against all serotypes (1-24) of , with negative results, between 28 and 60 days from the date of each collection of the [oocytes]
(1) and/or	[II.4.7.5.		ubjected to an agent identification test for bluetongue virus (serotypes 1-24), with negative sample taken on the date of collection of the [oocytes] (1) [embryos] (1);
II.4.8.	comply with	n at least one of the	e following conditions as regards infection with epizootic haemorrhagic disease virus (EHDV):
(1) either	[II.4.8.1.	in a third country	rept for at least 60 days prior to the date of and during collection of the [oocytes] (b) or territory, or zone thereof where EHDV has not been reported within a radius of 150 km of the r at least the preceding 2 years;]
(1)(15) or	[II.4.8.2.		ept in a seasonally disease-free zone, during the seasonally disease-free period, for at least 60 date of and during collection of the [oocytes] (1) [embryos] (1);]
(1) and/or	[II.4.8.3.		ept in a vector-protected establishment for at least 60 days prior to the date of and during [oocytes] (1) [embryos] (1);]
(1) or	[II.4.8.4.	were resident in following seroty	the third country or territory of dispatch to the Union in which according to official findings the pes of EHDV exist:

Certificate model OV/CAP-OOCYTES-EMB-A-ENTRY

II.a Certificate reference

HALL KINGD	03.6					II.a Ceruncate reference
NITED KINGD	<u>OM</u>	(1) either	[II.4.8.4.1.	0.00001	logical test able to detect specific antibodies against	those construes of EUDV with
		Veliner	[11.4.6.4.1.	negativ	ve results, on blood sample taken between 28 and 6 ocytes] (1) [embryos] (1);	
		(1) and/or	[II.4.8.4.2.		nt identification test for EHDV, with negative resultion of the [oocytes] (1) [embryos] (1).]]	ts, on blood sample taken on the date of
	⁽⁸⁾ [II.4.9.	comply wi	th the followin		ions as regards classical scrapie:	
	[11.1.5.	II.4.9.1.		-	continuously since birth in a third country or territor	ry where the following conditions are
		11.1.7.11.	fulfilled	-	solution and the country of territor	y where the following conditions the
			II.4.9.1	.1.	classical scrapie is compulsorily notifiable;	
*			II.4.9.1	.2.	an awareness, surveillance and monitoring syster	n is in place;
•	-0		II.4.9.1	.3.	ovine and caprine animals affected with classical destroyed;	scrapie are killed and completely
	O,		II.4.9.1	.4.	the feeding to ovine and caprine animals of meat- origin, as defined in the Terrestrial Animal Health Animal Health, has been banned and effectively of 7 years;	h Code of the World Organisation for
	⁽¹⁾ either	įн.4.9.2.	dispate require 999/20	th to the Uments se 01, exception with	continuously for the last 3 years preceding the date Union in a holding or holdings which has/have fulfit out in Chapter A, Section A, points 1.3.(a) to (f), opt during the period when they were kept at a sement the conditions set out in in Chapter A, Section A, part of the conditions of the conditi	lled during that period all the of Annex VIII to Regulation (EC) No nollection centre that complied durin
(1) or	[II.4.9.2.			animals and the embryos	
		(1) 6			ARR prion protein genotype;]	
		(1)	or [carry a	at least o	ne ARR allele.]]]	
II.5.	The [oocytes	s] ⁽¹⁾ [embryo	s] (1) described	in Part I		
I	I.5.1.				nd stored in accordance with animal health requirement (EU) 2020/686;	nents set out in [Part 2] (1) [Part 3] (1) [P
I	I.5.2.				ages on which the mark is applied in accordance wation (EU) 2020/692 and that mark is indicated in b	
I	I.5.3.	are transpo	orted in a conta	ainer whi	ch:	
		II.5.3.1.	responsit indicated	bility of t l in box I		and the seal bears the number as
		II.5.3.2.	has been	cleaned	and either disinfected or sterilised before use, or is	single-use container;
	(1) (8)	[11.5.5.5.			with a cryogenic agent which has not been previou	sly used for other products;
(1) (10)	II.5.4.	-		_	ages which are securely and hermetically sealed;	
	1.5.5.	placed in	secondary prote	ective ba		•
(I)(II) [II.6.	artificial in storage cer zone therec authority o	semination untre approved of listed in A f a Member	Ising semen con I for the collect nnex X to Impl State, and were	oming from tion, proc dementing e collecte	uced embryos] ⁽¹⁾ [micromanipulated embryos] ⁽¹⁾ of m a semen collection centre, germinal product processing or storage of semen by the competent author g Regulation (EU) 2021/404 for semen of ovine and processed and stored in accordance with the requant to Delegated Regulation (EU) 2020/686.]	essing establishment or germinal proc rity of a third country or territory, or d caprine animals or by the competent direments of Part 3. Chapter I and Part
⁽¹⁾⁽¹²⁾ [II.7.	The follow	ing antibioti	c or mixture of	antibioti	ics (13) has been added to the collection, processing,	

Notes

This animal health certificate is intended for the entry into the Union of oocytes and embryos of ovine and caprine animals, including when the Union is not the final destination of the oocytes and embryos.

In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland/Northern Ireland in conjunction with Annex 2 to that Protocol, references to the Union in this animal health certificate include the United Kingdom in respect of Northern Ireland.

This animal health certificate shall be completed in accordance with the notes for the completion of certificates provided for in Chapter 4 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

Part I:

Box reference I.11: "Place of dispatch": Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos. Only embryo collection or production teams

Certificate model OV/CAP-OOCYTES-EMB-A-ENTRY II.a Certificate reference UNITED KINGDOM listed in accordance with Article 233(3) of Regulation (EU) 2016/429 on the Commission website: http://ec.europa.eu/food/animal/semen_ova/ovine/index_en.htm . "Place of destination": Indicate the address and unique registration or approval number of the establishment of Box reference I.12: destination of the consignment of oocytes or embryos. Box reference I.19: Seal number shall be indicated. Box reference I.24: Total number of packages shall correspond to the number of containers. Box reference I.27: "Type": Specify if in vivo derived embryos, in vivo derived oocytes, in vitro produced embryos or micromanipulated embryos. "Species": Select amongst "Ovis aries" or "Capra hircus" as appropriate. "Identification number": Indicate the identification number of each donor animal. "Identification mark": Indicate the mark on the straw or other packages where oocytes or embryos of the consignment "Date of collection/production": Indicate the date on which oocytes or embryos of the consignment were collected or Approval or registration number of plant/establishment/centre": Indicate the unique approval number of the embryo collection or production team by which oocytes or embryos of the consignment were collected or produced. Quantity": Indicate the number of straws or other packages with the same mark. "Test": Indicate for BTV-test: point II.4.7.4 and/or point II.4.7.5, and/or for EHD-test: point II.4.8.4.1 and/or point II.4.8.4.2, if relevant. Part II: Delete if not applicable. Only for a third country or territory, or zone thereof with an opening date in accordance with column 9 of the table in Part 1 of Annex II to Implementing Regulation (EU) 2021/404. Only embryo collection or production teams listed in accordance with Article 233(3) of Regulation (EU) 2016/429 on the Commission website: (3) http://ec.europa.eu/food/animal/semen_ova/owine/index (4) Applicable for ovine animals. (5) Applicable for caprine animals. (6) Option available only for the consignment of in vivo derived embryos. (7) Manual of the International Embryo Technology Society A procedural guide and general information for the use of embryo transfer technology emphasising sanitary procedures, published by the International Embryo Technology Society, 1 111 North Dunlap Avenue, Savoy, Illinois 61 874, USA (http://www.iets.org/). (8) Delete if the Union is not the final destination of the oocytes and embryos. (9) Applicable for frozen oocytes or embryos. (10) Applicable for consignments where oocytes, in vivo derived embryos, in vitro produced embryos and micromanipulated embryos of ovine or caprine animals are placed and transported in one container. (11) Does not apply to oocytes. (12) Mandatory attestation in case antibiotics were added. (13) Insert the name(s) of the antibiotic(s) added and its (their) concentration. (14) For the zones with an entry "SF-BTV" in column 7 of the table in Part 1 of Annex II to Implementing Regulation (EU) 2021/404. (15) For the zones with an entry "SF-EHD" in column 7 of the table in Part 1 of Annex II to Implementing Regulation (EU) 2021/404. Official veterinarian Name (in capital letters) Date Qualification and title

Signature

Stamp